文献速递前列腺癌

疑似前列腺癌序贯影像监测(SPROUT)研究方案:减少过度诊断与不必要活检并及时发现显著性癌

Sequential Imaging of Suspicion of Prostate Cancer: Reducing Overdiagnosis and Unnecessary Biopsy with Timely Diagnosis of Significant Cancer (SPROUT)-Prospective Multicentre Cohort Study Protocol.
PubMed 文献 · Eur Urol Oncol · 2026-06-04

SPROUT是一项多中心单臂2期试验,纳入503例活检初治、PI-RADS 3或PI-RADS 4且PSAD≤0.15 ng/ml/cm3的男性,以纵向PSA和MRI监测替代立即活检,仅在进展时触发活检。主要终点为减少阴性或ISUP GG1活检的比例及以研究终点活检为参考的ISUP GG≥2癌漏诊比例,安全性采用≤5%非劣效界值。

要点

  • 对PI-RADS 3或选择性PI-RADS 4且PSAD≤0.15 ng/ml/cm3男性,可先监测而非立即活检。
  • 监测方案为每6个月PSA、每年MRI,进展至PI-RADS 4且PSAD>0.15 ng/ml/cm3或PI-RADS 5时活检。
  • 48个月持续PI-RADS 3或4者行研究终点活检,安全性界值为漏诊ISUP GG≥2癌≤5%。

核心结论

  • 通过纵向PSAD与MRI监测延迟活检指征,可能减少过度诊断和不必要活检,同时以≤5%非劣效界值保障显著性癌检出。

研究设计与样本

  • SPROUT为2期、多中心、单臂试验,在荷兰7个中心纳入503例年龄>18岁、活检初治的男性。
  • 入组标准为PI-RADS 3,或PI-RADS 4且PSAD≤0.15 ng/ml/cm3。

主要发现

  • 原文为研究方案,未报告监测策略减少活检或漏诊癌的实际结果数值。

关键数值与推荐

  • 监测期间每6个月检测PSA、每年行MRI,最长4年。
  • 随访MRI无可疑病灶时降级为仅每半年PSA,生化进展时重新触发MRI。
  • 进展至PI-RADS 4且PSAD>0.15 ng/ml/cm3或PI-RADS 5时触发靶向活检。
  • 持续PI-RADS 3或4病灶48个月者行研究终点活检。
  • 安全性以≤5%非劣效界值评估仅研究终点活检发现的ISUP GG≥2癌漏诊。

临床怎么用

  • 对PI-RADS 3或选择性PI-RADS 4且PSAD≤0.15 ng/ml/cm3的活检初治男性,可考虑以纵向PSA和MRI监测替代立即活检。
  • 监测中按PSAD和PI-RADS进展触发活检,48个月持续病灶行终点活检以评估漏诊风险。

局限性

  • 非随机设计可能导致选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Overdiagnosis of clinically insignificant prostate cancer (International Society of Urological Pathology Grade Group 1 [ISUP GG1]) remains a concern. Many men with Prostate Imaging Reporting and Data System (PI-RADS 3) or selected PI-RADS 4 lesions have no cancer or only ISUP GG1 on biopsy. A strategy of deferred decision-making on biopsy indication using longitudinal information may reduce overdiagnosis and biopsy burden. The SPROUT trial evaluates longitudinal prostate-specific antigen density (PSAD) and magnetic resonance imaging (MRI) monitoring, triggering biopsy only upon progression while preserving safety for detecting clinically significant (ISUP GG ≥2) cancer. CLINICAL TRIAL DESIGN AND TIMEFRAME: The SPROUT study is a phase 2, multicentre, single-arm trial across seven Dutch centres, enrolling 503 biopsy-naïve men aged >18 yr with PI-RADS 3, or PI-RADS 4 with PSAD ≤ 0.15 ng/ml/cm3. Instead of immediate biopsy, participants undergo PSA testing every 6 mo and annual MRI for up to 4 yr. If follow-up MRI shows no suspicious lesion, monitoring de-escalates to twice-yearly PSA testing alone, with MRI retriggered in the event of subsequent biochemical progression. Targeted biopsies are triggered by progression to PI-RADS 4 with PSAD >0.15 ng/ml/cm3 or PI-RADS 5. Men with persistent PI-RADS 3 or 4 lesions after 48 mo undergo an end-of-study biopsy. Image quality is assessed using a standardised scoring system for Prostate Image Quality (PI-QUAL) version 2. ENDPOINTS: Primary endpoints are the proportion of avoided biopsies that would have been negative or ISUP GG1 (effectiveness), and the proportion of ISUP GG ≥ 2 cancers missed by monitoring, using the end-of-study biopsy as the reference (safety). Secondary endpoints include grade shifts, detection of ISUP GG ≥ 3, health-related quality of life (EPIC-26, short STAI-6), and cost-effectiveness. DATA SOURCES AND STATISTICAL ANALYSIS: Safety will be assessed using a ≤5% noninferiority margin for missed ISUP GG ≥ 2 cancers, defined as cases detected only at end-of-study biopsy. Effectiveness will be measured by ISUP GG1 and negative biopsy rates. STRENGTHS AND LIMITATIONS: Strengths include the intermediate-term follow-up and MRI quality control during the study. Limitations include the nonrandomised design, which might result in selection bias. ETHICS AND TRIAL REGISTRATION: This trial was approved by the Medical Research Ethics Committee Utrecht (ClinicalTrials.gov, NCT07180381). PATIENT SUMMARY: Not all prostate cancers require treatment. This study focuses on men with an intermediate risk of harbouring aggressive prostate cancer, based on PSA blood levels and MRI findings. Instead of undergoing immediate prostate biopsy, participants are closely monitored with PSA testing every 6 mo and MRI annually over a 4-yr period. A biopsy is performed only if there are signs of disease progression. If no biopsy has been performed during the study but a lesion remains visible on the final MRI, end-of-study biopsies will be conducted to assess any potentially missed aggressive cancers. This approach aims to reduce unnecessary biopsies and avoid overdiagnosis of nonaggressive prostate cancers, while still ensuring timely detection of cancers that require treatment.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sweere V, de Rooij M, Kil PJM, et al. Sequential Imaging of Suspicion of Prostate Cancer: Reducing Overdiagnosis and Unnecessary Biopsy with Timely Diagnosis of Significant Cancer (SPROUT)-Prospective Multicentre Cohort Study Protocol. Eur Urol Oncol. 2026. PMID: 42242939. doi:10.1016/j.euo.2026.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。